Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Bearish
4
Neutral
1
Bullish
9
Bearish
36
Neutral
1
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
4
Neutral
1
Bullish
9
Bearish
4
Neutral
1
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Coral Laboratories Limited (CLL) is a pharmaceutical company focused on manufacturing generic branded, nutraceuticals, OTC, and herbal medicines across India.
The company operates three production facilities located in Daman and Dehradun, enhancing its manufacturing capacity and scope.
Originally promoted by Navin B Doshi of the DWD group, Coral Labs raised Rs. 2.5 crores through a public issue to expand its manufacturing capabilities.
Coral Laboratories began commercial production at its ultra-modern unit in Daman in March 2004 and its plant in Dehradun in September 2006.
Pharmaceuticals & Biotechnology
Pharmaceuticals
176 Cr
Low Risk
9.2
34.8
0.2
0.8
679.00
360.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
131.25 | 179 Cr | -6.78 | 7.50 | 0.00 | -148.86 | -9.23 | -19.10 | ||
494.10 | 176 Cr | 9.18 | 0.84 | 0.40 | 7.83 | 10.89 | 7.98 | ||
58.02 | 171 Cr | 12.94 | 1.39 | 0.00 | 20.04 | 19.30 | 8.92 | ||
46.07 | 170 Cr | -12.56 | 0.00 | 0.00 | 41.16 | -26.02 | -11.34 | ||
6.96 | 168 Cr | 524.94 | 4.79 | 0.00 | 0.90 | 1.13 | 0.84 | ||
20.17 | 167 Cr | 12.11 | 2.22 | 0.00 | 17.38 | 20.98 | 9.01 | ||
31.03 | 166 Cr | 27.10 | 1.16 | 0.00 | 8.93 | 13.60 | 2.10 | ||
| Median: 7 Co. | — | 46.07 | 170 Cr | 12.11 | 1.39 | 0.00 | 8.93 | 10.89 | 2.10 |
Coral Laboratories Ltd (CORALAB) is currently trading at 494.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Coral Laboratories Limited (CLL) is a pharmaceutical company focused on manufacturing generic branded, nutraceuticals, OTC, and herbal medicines across India. The company operates three production facilities located in Daman and Dehradun, enhancing its manufacturing capacity and scope. Originally promoted by Navin B Doshi of the DWD group, Coral Labs raised Rs. 2.5 crores through a public issue to expand its manufacturing capabilities. Coral Laboratories began commercial production at its ultra-modern unit in Daman in March 2004 and its plant in Dehradun in September 2006.
Over the past 52 weeks, Coral Laboratories Ltd has traded between a low of ₹360.00 and a high of ₹679.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Coral Laboratories Ltd has a market capitalization of approximately 176.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Coral Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 176.39 Cr, Coral Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Coral Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Coral Laboratories Ltd is 9.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company reported a Q1FY27 net profit of ₹4.414 crore for the quarter ended June 30, 2026.
